English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
TürkçeHealth Catalyst (HCAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended September 2025, Health Catalyst (HCAT) reported revenue of $76.32 million, representing no change compared to the same period last year. EPS came in at $0.06, compared to $0.07 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $75.08 million, representing a surprise of +1.66%. The company delivered an EPS surprise of +20%, with the consensus EPS estimate being $0.05.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Health Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Professional services: $24.27 million versus the four-analyst average estimate of $23.08 million. The reported number represents a year-over-year change of -12.4%. Revenue- Technology: $52.05 million versus $52 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7% change. Adjusted Gross Profit- Professional Services: $4.63 million compared to the $4.45 million average estimate based on four analysts. Adjusted Gross Profit- Technology: $35.5 million versus $34.9 million estimated by four analysts on average.View all Key Company Metrics for Health Catalyst here>>>
Shares of Health Catalyst have returned +6.8% over the past month versus the Zacks S&P 500 composite's +0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Health Catalyst, Inc. (HCAT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).